Year: 2016
Type: review
Abstract: PURPOSE: Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunotherapy with cytokines in metastatic renal cell carcinoma (mRCC). METHODS: A panel of experts convened to review currently available phase 3 data for mRCC treatment of approved agents, in addition to available EAU guideline data for a collaborative review as the plurality of substances offers different options of first-, second- and third-line treatment with potential sequencing. RESULTS: Sunitinib and pazopanib are approved treatments in first-line therapy for patients with favorable- or intermediate-risk clear cell RCC (ccRCC). Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with non-clear cell RCC (non-ccRCC). In the second-line treatment TKIs or mTOR inhibitors are treatment choices. Therapy options after TKI failure consist of everolimus and axitinib. Available third-line options consist of everolimus and sorafenib. Recently, nivolumab, a programmed death-1 (PD1) checkpoint inhibitor, improved overall survival benefit compared to everolimus after failure of one or two VEGFR-targeted therapies, which is likely to become the first established checkpoint inhibitor in mRCC. Data for the sequencing of agents remain limited. CONCLUSIONS: Despite the high level of evidence for first and second-line treatment in mRCC, data for third-line therapy are limited. Possible sequences include TKI-mTOR-TKI or TKI-TKI-mTOR with the upcoming checkpoint inhibitors in perspective, which might settle a new standard of care after previous TKI therapy.
Source: World Journal of Urology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: metastatic renal cell carcinoma, systemic therapy, VEGF antibody, VEGFR inhibitors, mTOR inhibitors, sunitinib, pazopanib, temsirolimus, interferon-alpha, everolimus, axitinib, sorafenib, nivolumab, PD-1 inhibitors, treatment sequencing, second-line therapy, third-line therapy, clear cell renal cell carcinoma, non-clear cell renal cell carcinoma
Open Access status: hybrid
Estimated APC paid: $4,390
Funder: Novartis Pharma
OpenAlex ID: W2409657626
